Skip to main content
ASN NEURO logoLink to ASN NEURO
. 2016 Sep 28;8(5):1759091416670749. doi: 10.1177/1759091416670749

Transcriptional Fingerprint of Hypomyelination in Zfp191null and Shiverer (Mbpshi) Mice

Joshua D Aaker 1,*, Benayahu Elbaz 1,*, Yuwen Wu 1,#a, Timothy J Looney 2,#b, Li Zhang 2, Bruce T Lahn 2, Brian Popko 1,
PMCID: PMC5046175  PMID: 27683878

Abstract

The transcriptional program that controls oligodendrocyte maturation and central nervous system (CNS) myelination has not been fully characterized. In this study, we use high-throughput RNA sequencing to analyze how the loss of a key transcription factor, zinc finger protein 191 (ZFP191), results in oligodendrocyte development abnormalities and CNS hypomyelination. Using a previously described mutant mouse that is deficient in ZFP191 protein expression (Zfp191null), we demonstrate that key transcripts are reduced in the whole brain as well as within oligodendrocyte lineage cells cultured in vitro. To determine whether the loss of myelin seen in Zfp191null mice contributes indirectly to these perturbations, we also examined the transcriptome of a well-characterized mouse model of hypomyelination, in which the myelin structural protein myelin basic protein (MBP) is deficient. Interestingly, Mbpshi (shiverer) mice had far fewer transcripts perturbed with the loss of myelin alone. This study demonstrates that the loss of ZFP191 disrupts expression of genes involved in oligodendrocyte maturation and myelination, largely independent from the loss of myelin. Nevertheless, hypomyelination in both mouse mutants results in the perturbation of lipid synthesis pathways, suggesting that oligodendrocytes have a feedback system that allows them to regulate myelin lipid synthesis depending on their myelinating state. The data presented are of potential clinical relevance as the human orthologs of the Zfp191 and MBP genes reside on a region of Chromosome 18 that is deleted in childhood leukodystrophies.

Keywords: cholesterol biosynthesis, hypomyelination, oligodendrocyte development, shiverer, transcriptional networks, ZFP191

Introduction

Oligodendrocytes are the cells that produce myelin in the vertebrate central nervous system (CNS). The majority of oligodendrocyte progenitor cells (OPCs) are derived from neural progenitor cells in the subventricular zone (Richardson et al., 2006). During CNS development, OPCs migrate along vasculature to their target axons where they terminally differentiate to mature oligodendrocytes, express myelin genes, produce myelin, wrap axons, and provide metabolic axonal support (Simons and Nave, 2015; Tsai et al., 2016).

OPCs are able to proliferate until they transit to their target axons where they undergo terminal differentiation, which is achieved through a delicate balance of both inhibitors and promoters of differentiation (Menn et al., 2006). Among the inhibitors of oligodendrocyte differentiation, the G-protein-coupled receptor 17 is an oligodendrocyte-specific receptor that strongly inhibits differentiation and may work by increasing the expression of inhibitors of differentiation 2 and 4 (ID2/ID4; Wang et al., 2001; Chen et al., 2009). ID2/ID4 along with Hes family bHLH transcription factors 1 and 5 (HES1/5) have been shown to enforce the proliferating OPC state and to repress terminal differentiation (Wu et al., 2003; Liu et al., 2006). In addition, the Notch and Wnt signaling pathways have been implicated in suppressing oligodendrocyte differentiation (Wang et al., 1998; Fancy et al., 2009; Nakatani et al., 2013). Wnt signals were shown to be upstream of bone morphogenetic protein signaling (Feigenson et al., 2011), which was shown to inhibit oligodendrocyte differentiation (Grinspan et al., 2000; Miller et al., 2004; Samanta and Kessler, 2004; See et al., 2004; Cheng et al., 2007). Despite the inhibitory effect of the Wnt signaling pathway on oligodendrocyte differentiation, the Wnt effector transcription factor 4 promotes oligodendrocyte differentiation (Fancy et al., 2009; Hammond et al., 2015).

Among the promoters of differentiation, oligodendrocyte transcription factor 2 promotes differentiation of oligodendrocytes by recruiting the chromatin-remodeling enzyme SWI/SNF related, matrix associated, actin-dependent regulator of chromatin, subfamily a, member 4 (SMARCA4/BRG1) to regulatory elements of key genes, including Zfp191 and Sox10 during differentiation (Yu et al., 2013). SRY (sex determining region Y)-box 10 (SOX10) is required for the generation of myelinating oligodendrocytes and is a direct activator of several myelin-related genes (Li et al., 2007). One of the genes controlled by SOX10 is myelin regulatory factor (MYRF; Hornig et al., 2013). SOX10 binds in the first intron of the MYRF gene and induces its expression during oligodendrocyte differentiation. Following its induction, MYRF mediates the progression of premyelinating oligodendrocytes to a mature, myelinating state (Emery et al., 2009). MYRF and SOX10 target many of the same myelin gene enhancers and promoters but also appear to target individual enhancers independently of the other (Bujalka et al., 2013; Hornig et al., 2013).

Previous work from our laboratory (Howng et al., 2010) has demonstrated that zinc finger protein 191 (ZFP191, also known as ZFP24) is required for oligodendrocyte differentiation. We have shown that many of the oligodendrocyte-specific genes induced during oligodendrocyte differentiation (including abundantly expressed myelin genes such as Mbp and Plp1) are reliant on ZFP191 for their expression (Howng et al., 2010); however, the full spectrum of genes that are affected by loss of ZFP191 was unknown. Therefore, we characterize here the effect of Zfp191 loss on the whole transcriptome by high-throughput RNA sequencing (RNA-seq).

ZFP191 contains a SCAN domain that may be involved in protein–protein interaction (Williams et al., 1999) and four C2H2 zinc finger domains that bind DNA (Wang et al., 2008). ZFP191 is a member of the C2H2 zinc-finger protein family, many members of which are known to be DNA binding proteins that function as transcriptional regulators (Edelstein and Collins, 2005). Consistent with this, we find that loss of Zfp191 results in substantial changes in the transcriptome of the whole brain and in the transcriptome of cultured oligodendrocyte lineage cells.

To examine whether the substantial changes in the transcriptome in the Zfp191null mice CNS are due to the direct loss of ZFP191 or whether they represent a secondary consequence of the inability to produce myelin, we performed RNA sequencing using the shiverer mouse, which is a model of hypomyelination that resulted from a spontaneous null mutation in the gene encoding the structural myelin protein, myelin basic protein (MBP; Roach et al., 1985). We find that unlike hypomyelination originating from the lack of Zfp191, the effect of the MBP mutation on the transcriptome was minor, suggesting that the loss of ZFP191 disrupts transcripts involved in oligodendrocyte maturation and myelination largely independent from the loss of myelin. Interestingly, the loss of myelin in both mouse mutants, however, results in the perturbation of the cholesterol biosynthesis pathway.

Materials and Methods

Animal Work

Generation of Zfp191null mice on the C57BL/6J background has been previously described (Howng et al., 2010). The C3Fe.SWV-Mbpshi/J shiverer strain of mice was purchased from The Jackson Laboratory (stock 001428) and has been previously described (Readhead et al., 1987). All animal procedures were conducted in complete compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the University of Chicago.

Cell Culture

Primary OPCs were isolated from brain and enzymatically and mechanically dissociated as previously described (Emery and Dugas, 2013). Briefly, both cortices were removed and cells were dissociated by enzymatic and mechanical methods. The single cell suspension was then immunopanned on two plates coated with 50 mM Tris-HCl pH = 9.5 and goat anti-mouse IgG + IgM (Jackson ImmunoResearch, 115-055-044) and one plate coated in 50 mM Tris-HCl with goat anti-mouse IgM, µ-chain specific (Jackson ImmunoResearch, 115-005-020). These plates were then sequentially incubated with rat neural antigen 2 (Ran-2), galactocerebroside (GC), and oligodendrocyte marker (O4) hybridomas, respectively, in 0.2% bovine serum albumin and Dulbecco's phosphate-buffered saline (Life Technologies #14040133). The plates served as two sequential negative selection plates coated with Ran-2 and GC hybridomas followed by a positive selection plate coated with O4 hybridoma. The Ran-2 immunopanning captures type 1 astrocytes and meningeal cells (Bartlett et al., 1981). The GC immunopanning captures differentiated oligodendrocytes (Sommer and Schachner, 1981). The O4 hybridoma is able to capture O-2A progenitor cells (Sommer and Schachner, 1981). Cells were then trypsinized (0.25% in Earle's balanced salt solution, Life Technologies #14155063) and plated on poly-d-lysine coated plates. Cells were maintained in Sato serum-free Dulbecco's modified Eagle medium (Life Technologies #11960069) as previously described with the addition of B27 supplement (Life Technologies #17504044; Dugas et al., 2006). For proliferation media, platelet-derived growth factor-AA (PDGF-AA; 10 ng/ml, PeproTech #100-13A), neurotrophin-3 (1 ng/ml, PeproTech #450-03), forskolin (Sigma Aldrich [0.01 mM]), and ciliary neurotrophic factor (CNTF; 10 ng/ml, PeproTech #450-13) were added. To stimulate differentiation, PDGF-AA was removed and triiodothyronine (40 ng/ml, Sigma # T6397) was added. Media was changed every other day and differentiated cells were collected after 5 days.

RNA Sequencing

For whole-brain RNA sequencing, mice were anesthetized with avertin (0.5% 2,2,2-tribromoethanol; Sigma-Aldrich #T48402; w/v), 0.5% tert-amyl alcohol; Fluka #PHR1667; v/v) in MillQ water) used at 100 μl per 10 g body weight, and the cerebral hemispheres were removed and snap frozen at −80 ℃ at postnatal Day 21. Total RNA was isolated using Aurum Total RNA Fatty and Fibrous Tissue Kit (Bio-Rad #732-6830) following the manufacturer's protocol. OPC and oligodendrocyte total RNA was collected using Aurum Total RNA Kit (Bio-Rad #732-6820). Two biological replicates were used for all samples. The quality of the RNA was assessed using an Agilent 2100 Bioanalyzer. RNA sequencing libraries were prepared using Illumina TruSeq RNA sample Kit (#RS-122-2001) and sequenced by HiSeq 2000 and HiSeq 2500 sequencers using HiSeq SBS Kit (Illumina #FC-401-4002) at the University of Chicago Functional Genomics Facility. Sequencing data have been uploaded to Sequence Read Archive from the National Center for Biotechnology Information through the National Library of Medicine under accession number PRJNA338665.

Bioinformatics

RNA sequencing reads were mapped to the mm9 genome using BowTie v.1 and the ExpressionPlot pipeline (Langmead et al., 2009; Friedman and Maniatis, 2011). Differential expression was performed using DEseq in the ExpressionPlot software package (Anders and Huber, 2010). The Bonferroni correction was used within DEseq to control for multiple comparisons. Only transcripts ≥0.5 Reads per Kilobase per Million (RPKM) mapped reads, ≥1.5-fold change, and p < .001 were analyzed. p Value of 8.28 × 10−307 or lower was rounded to zero. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was performed using DAVID (Kanehisa and Goto, 2000; Huang da et al., 2009a, 2009b; Kanehisa et al., 2014). The Galaxy environment was used to compare datasets (Giardine et al., 2005; Blankenberg et al., 2010; Goecks et al., 2010). Cellular identity stratification was done using the online RNA-Seq transcriptome and splicing database (http://web.stanford.edu/group/barres_lab/brain_rnaseq.html; Zhang et al., 2014). The top 500 transcripts for each cell identity from the database were compiled in order to allow for cell-type comparison and grouping from our results.

Real-Time PCR

RNA was collected using Aurum Total RNA Kit (Bio-Rad #732-6820). RNA integrity was verified using Agilent chip (Agilent Technologies). cDNA was generated using iScript cDNA Synthesis Kit (Bio-Rad #1708890) following the manufacturer's protocol. Real-time polymerase chain reaction (PCR) was performed on the cDNA using iQ SYBR Green Supermix (Bio-Rad #1708882) using a CFX96 Touch Deep Well Real-Time PCR Detection System (Bio-Rad #1854095). Each sample was done in triplicate. Relative expression from amplified cDNA samples was determined using the 2-ΔΔCT method (Pfaffl, 2001). The primers sequences for all the transcripts that were selected for analysis are in Table S1. The expression of the selected transcripts was normalized to the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (Hprt) cDNA.

Results

Loss of Zfp191 Expression Perturbs the Whole Brain Transcriptome

Previous work has shown that ZFP191 is required for CNS myelination. Nonetheless, the role that ZFP191 plays in normal myelin production by oligodendrocytes is not well understood (Howng et al., 2010). To examine the potential role of ZFP191 in transcriptional regulation of CNS myelination, we used RNA sequencing to examine changes in the transcriptome. RNA sequencing was performed on postnatal Day 21 (P21) and whole-brain RNA samples were taken from Zfp191null and Zfp191+/+ littermates. The levels of 394 transcripts were determined to be significantly different in the Zfp191null brains compared with Zfp191+/+ brains (Tables S2 and S3). The majority of the perturbed Zfp191null brain transcripts displayed reduced levels of expression in the mutant animals.

The loss of ZFP191 resulted in the decreased expression of 327 transcripts when compared with the Zfp191+/+ CNS transcriptome (Table S2). Several transcripts that encode key myelin proteins, such as MBP and myelin oligodendrocyte glycoprotein (MOG; Matthieu and Amiguet, 1990), were identified as having decreased transcript levels. We also observed that transcripts that encode key oligodendrocyte transcriptional factors such as SOX10 and MYRF had reduced expression with loss of ZFP191 along with downstream targets of MYRF, such as the transcript for ring finger and FYVE-like domain containing E3 ubiquitin protein ligase (Rffl; Bujalka et al., 2013).

Table 1A and B show the top 10 transcripts based on expression level, as determined by RPKM values, and fold change, respectively, that have reduced expression in the Zfp191null whole brain. Transcripts with reduced expression in the Zfp191null brain were analyzed for changes in characterized pathways using the KEGG (Kanehisa and Goto, 2000; Kanehisa et al., 2014). The steroid biosynthesis pathway is significantly disturbed due to disruption of transcripts that encode key biosynthetic pathway proteins such as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), fatty acid 2-hydroxylase (FA2H), and 24-dehydrocholesterol reductase (Saher and Simons, 2010; Table S2). Proper synthesis of cholesterol is known to be required for production of compact myelin in oligodendrocytes (Saher et al., 2005).

Table 1.

Top 10 Transcripts That Have Reduced Expression in Zfp191null Whole Brains.

Gene Fold change Zfp191+/+ RPKM
A. Genes sorted by Zfp191+/+ transcript RPKM
Plp1 8.39 1210.00
Mbp 6.06 749.00
Cldn11 6.62 258.00
Mal 9.57 222.00
Cnp 3.33 207.00
Mobp 13.82 129.00
Mag 10.87 117.00
Mog 7.27 111.00
Ugt8a 10.56 111.00
Tspan2 5.20 110.00
B. Genes sorted by fold change for Zfp191+/+
Gjb1 15.08 14.90
Mobp 13.82 129.00
Gjc2 11.53 12.20
Mag 10.87 117.00
Plekhh1 10.63 7.72
Ugt8a 10.56 111.00
A230069A22Rik 9.73 24.90
Mal 9.58 222.00
Ermn 9.12 35.10
Plp1 8.39 1210.00

RNA sequencing was performed on Zfp191null and Zfp191+/+ whole-brain RNA samples (n = 2 for each genotype). Transcripts listed for Zfp191+/+ whole brains in A had a p < .001 fold change when comparing Zfp191+/+ versus Zfp191null whole brains and are sorted by RPKM value. Transcripts listed for Zfp191+/+ whole brains in B had a RPKM value ≥7, a p < .001 fold change when comparing Zfp191+/+ versus Zfp191null whole brains, and are sorted by fold changes.

Loss of Zfp191 Expression Mainly Affects Cell-Specific Transcripts in the Oligodendrocyte Lineage Along With Key Signaling Cascades

To determine the cells that are most affected by the loss of ZFP191 in the brain, we stratified the 394 differentially expressed transcripts (Tables S2 and S3) into cell-specific identities (oligodendrocyte lineage, neuron, astrocyte, microglia, endothelia, or noncell specific) using the online RNA-Seq transcriptome and splicing database (Zhang et al., 2014). Strikingly, of the 327 transcripts that had lower expression levels with loss of ZFP191, 221 transcripts were associated with oligodendrocyte lineage cells (Figure 1).

Figure 1.

Figure 1.

Loss of Zfp191 expression mainly perturbs transcripts associated with the oligodendrocyte lineage in the whole brain. Number of transcripts with decreased expression by loss of ZFP191 (A) or increased expression (B) sorted into cellular identity categories using data from Zhang et al. (Zhang et al., 2014). Note. ZFP191 = zinc finger protein 191.

Loss of Zfp191 expression increased the mRNA levels of 67 transcripts in the mutant CNS; 10 transcripts with the most abundant RPKM are listed in Table 2 (the full list is in Table S3). One transcript that was increased encodes glial fibrillary acidic protein (Gfap; Bignami et al., 1972), which may suggest astrogliosis. This is supported by a 2.5-fold increase in serine peptidase inhibitor, clade A, member 3N (Serpina3n), which has been shown to display increased expression in reactive astrocytes (Zamanian et al., 2012). In addition, there were increases in multiple transcripts that encode complement factors and chemokine ligands that are expressed by microglia (Zhang et al., 2014) that account for 39% of the elevated transcripts. KEGG pathway analysis indicated that complement, chemokine signaling, and Toll-like receptor pathways are increased with loss of ZFP191 in the whole brain. Unlike the transcripts that had decreased expression, which were mostly associated with oligodendrocyte lineage cells (Figure 1(a)), transcripts that have higher expression levels with loss of ZFP191 were more often noncell specific or associated with gliosis (Figure 1(b)). This may suggest that loss of Zfp191 expression may perturb cells indirectly by disrupting normal oligodendrocyte maturation and function.

Table 2.

Top 10 Transcripts That Have Increased Expression in Zfp191null Whole Brains.

Gene Fold change Zfp191null RPKM
Genes sorted by Zfp191null transcript RPKM
Apoe 1.60 1050.00
Mt1 1.61 452.00
Mt2 1.53 303.00
Fam107a 1.70 161.00
Gfap 1.97 106.00
Ctss 1.69 33.90
C1qa 1.66 29.00
C1qb 1.70 28.20
Gabra2 1.62 21.40
C1qc 1.82 16.20

RNA sequencing was performed on Zfp191null and Zfp191+/+ whole brains (n = 2 for each genotype). Transcripts listed for Zfp191null whole brains had a p < .001 fold change when comparing Zfp191null versus Zfp191+/+ whole brains and are sorted by RPKM value.

Loss of ZFP191 Perturbs the Transcriptome of OPCs

Because the loss of ZFP191 in the whole brain predominantly disrupts oligodendrocyte lineage-specific transcripts, we wanted to further explore this effect in purified primary cells. We therefore isolated and cultured OPCs from both Zfp191null and Zfp191+/+ brains. Half of these cells were allowed to differentiate into mature oligodendrocytes. Both cell types from each genotype were then collected for RNA sequencing analysis. We discovered that the absence of ZFP191 during the OPC stage perturbs 444 transcripts (Tables S4 and S5), of which 160 transcripts had decreased expression. Tables 3A and B lists the transcripts that are most abundant in the Zfp191+/+ OPCs and their corresponding reduction with the loss of ZFP191. Transcripts involved in many signal transduction pathways were disturbed including delta-like 1 and 3 (Dll1, Dll3), which are involved in the Notch pathway and SRY (sex determining region Y)-box 9 (Sox9), which is involved in cAMP signaling (Grandbarbe et al., 2003; Tsuda et al., 2003). KEGG analysis demonstrated that Notch, mitogen-activated protein kinase (MAPK), calcium signaling, and focal adhesion pathways were disrupted with loss of ZFP191 in OPCs.

Table 3.

Top 10 Transcripts That Have Reduced Expression in Zfp191null OPCs.

Gene Fold change Zfp191+/+ RPKM
A. Genes sorted by Zfp191+/+ transcript RPKM
Ptn 1.77 265.00
Bcan 1.99 178.00
Gpr56 2.17 119.00
Add3 2.18 101.00
Dll1 1.82 61.50
Tubb6 2.78 63.40
Rev3l 1.98 43.90
Chrna4 2.33 47.10
Pnmal2 1.75 35.30
Slc38a1 1.78 34.70
B. Genes sorted by fold change for Zfp191+/+
Matn4 27.70 27.40
Pstpip2 15.27 16.70
Pcdh11x 5.77 9.14
9030025P20Rik 5.24 10.90
Dll3 4.92 38.60
Col18a1 4.71 10.20
Hddc3 4.15 30.10
Tmem179 4.13 11.70
Kifc3 3.98 59.10
Lmo3 3.92 15.30

RNA sequencing was performed on RNA samples isolated from Zfp191null and Zfp191+/+ OPCs cultured in vitro (n = 2 for each genotype). Transcripts listed for Zfp191+/+ OPCs in A had a p < .001 fold change when comparing Zfp191+/+ versus Zfp191null OPCs and are sorted by RPKM value. Transcripts listed for Zfp191+/+ OPCs in B had a RPKM value ≥7, a p < .001 fold change when comparing Zfp191+/+ versus Zfp191null OPCs, and are sorted by fold changes.

Loss of ZFP191 results in 284 transcripts being expressed at a higher level than in Zfp191+/+ OPCs (Table 4A and B). Of these, transcripts such as Id2, SRY (sex determining region Y)-box 5 (Sox5), and Nkx6.2 are known to be downregulated when OPCs stop proliferating (Wang et al., 2001). In addition, in the absence of ZFP191, histone deactylase 1 (Hdac1) is highly expressed along with wingless-type mouse mammary tumor virus integration site family member 7A (Wnt7a), both of which code for proteins that have been shown to be involved in the maintenance of the progenitor state (Ye et al., 2009; Yuen et al., 2014). Loss of ZFP191 also causes several transcripts associated with disruption to the MAPK and Wnt signaling pathways to be more abundant. Overall, these analyses demonstrate that the Zfp191 mutation disrupts gene expression in the oligodendrocyte lineage more than previously speculated.

Table 4.

Top 10 Transcripts That Have Increased Expression in Zfp191null OPCs.

Gene Fold change Zfp191null RPKM
A. Genes sorted by Zfp191null transcript RPKM
Fscn1 1.82 360.00
Rps26 1.91 249.00
Npy 64.28 214.00
Vgf 24.33 214.00
Olfm1 8.11 131.00
Id2 3.80 131.00
Wnk2 20.09 123.00
Tgfa 1.76 116.00
Elfn1 3.90 89.80
Mn1 50.44 79.80
B. Genes sorted by fold change for Zfp191null
Pax7 24760.00 15.40
Tmem119 936.10 7.82
Epha2 934.90 41.10
Rps3a 261.00 44.90
Rps18 240.60 42.10
Ebi3 72.15 17.10
Npy 64.28 214.00
Mn1 50.44 79.80
Kcnip1 33.72 73.00
Tspan18 31.19 16.60

RNA sequencing was performed on RNA samples isolated from Zfp191null and Zfp191+/+ OPC cultured in vitro (n = 2 for each genotype). Transcripts listed for Zfp191null OPCs in A had a p < .001 fold change when comparing Zfp191null versus Zfp191+/+ OPCs and are sorted by RPKM value. Transcripts listed for Zfp191null OPCs in B had a RPKM value ≥7, a p < .001 fold change when comparing Zfp191null versus Zfp191+/+ OPCs, and are sorted by fold changes.

Loss of ZFP191 Perturbs Key Cell Signaling Pathways in Mature Oligodendrocytes

The absence of ZFP191 perturbs the mRNA levels of 5,564 transcripts in mature oligodendrocytes (Tables S6 and S7). Over 45%, or 2,513, transcripts have decreased abundance with loss of ZFP191 in oligodendrocytes. Transcripts for Sox10, Myrf, Mbp, Mog, Nkx6.2, and G protein-coupled receptor 37 (Gpr37), all known to code for proteins that play a significant role in myelination (Emery, 2010b), are decreased with loss of Zfp191 expression (Table 5A and B). Many KEGG-identified pathways are perturbed in mutant oligodendrocytes including regulation of actin cytoskeleton, receptor tyrosine-protein kinase erbB-3 (Erbb), MAPK, sphingomyelin metabolism, and focal adhesion. Transcripts that were more abundant (3,051) in the Zfp191null oligodendrocytes compared with Zfp191+/+ oligodendrocytes include PDGF receptor alpha polypeptide (PDGFra), sex determining region Y-box 4 (Sox4), and myelocytomatosis oncogene (c-Myc) along with the known differentiation repressors Id2/4 and Hes1/5 (Table 6A and B).

Table 5.

Top 10 Transcripts That Have Reduced Expression in Zfp191null Oligodendrocytes.

Gene Fold change Zfp191+/+ RPKM
A. Genes sorted by Zfp191+/+ transcript RPKM
Plp1 6.64 8140.00
Tubb4 3.53 3790.00
Cldn11 5.27 3730.00
Mbp 4.82 3560.00
Mag 12.04 2670.00
Cnp 4.07 2380.00
Fth1 2.03 1740.00
Mal 13.77 1180.00
Aplp1 3.01 852.00
Mobp 17.51 841.00
B. Genes sorted by fold change for Zfp191+/+
Gjb1 381.34 181.00
Ly6a 132.40 19.30
Clmn 102.45 47.10
Vamp5 72.49 18.70
Rab37 64.52 7.69
Esyt3 63.85 7.10
C030030A07Rik 60.74 14.90
Pls1 57.19 54.70
Padi2 56.62 88.90
Pdlim2 46.26 180.00

RNA sequencing was performed on RNA samples isolated from Zfp191null and Zfp191+/+ oligodendrocytes cultured in vitro (n = 2 for each genotype). Transcripts listed for Zfp191+/+ oligodendrocytes in A had a p < .001 fold change when comparing Zfp191+/+ versus Zfp191null oligodendrocytes and are sorted by RPKM value. Transcripts listed for Zfp191+/+ oligodendrocytes in B had a RPKM value ≥7, a p < .001 fold change when comparing Zfp191+/+ versus Zfp191null oligodendrocytes, and are sorted by fold changes.

Table 6.

Top 10 Transcripts That Have Increased Expression in Zfp191null Oligodendrocytes.

Gene Fold change Zfp191null RPKM
A. Genes sorted by Zfp191null transcript RPKM
mt-Nd2 1.81 1610.00
Gfap 14.52 989.00
Fabp7 7.48 832.00
Vim 15.77 805.00
Apoe 5.10 795.00
Mt3 21.71 740.00
Ckb 2.02 612.00
Nnat 7.80 491.00
Mt1 2.50 348.00
Marcks 3.30 344.00
B. Genes sorted by fold change for Zfp191null
Rps18 2185.00 14.60
Rps3a 390.50 16.40
Npy 299.90 14.00
Acta2 253.00 33.40
Sod3 180.50 14.10
Ccnd2 166.80 46.50
Myl9 139.40 30.30
Ctgf 137.20 8.62
Glycam1 127.60 26.10
Gpc4 116.10 26.20

RNA sequencing was performed on RNA samples isolated from Zfp191null and Zfp191+/+ oligodendrocytes cultured in vitro (n = 2 for each genotype). Transcripts listed for Zfp191null oligodendrocytes in A had a p < .001 fold change when comparing Zfp191null versus Zfp191+/+ oligodendrocytes and are sorted by RPKM value. Transcripts listed for Zfp191null oligodendrocytes in B had an RPKM value ≥7, a p < .001 fold change when comparing Zfp191null versus Zfp191+/+ oligodendrocytes, and are sorted by fold changes.

Transcripts that are decreased due to loss of ZFP191 in cultured primary mature oligodendrocytes represent nearly 77% of transcripts that are also decreased in the whole brain (327 total transcripts decreased in the whole brain, 252 of which are also decreased in cultured primary mature oligodendrocytes; Figure 2). The transcripts that are decreased in both datasets include critical myelin-associated transcripts such as 2′,3′-cyclic nucleotide 3′ phosphodiesterase (Cnp), aspartoacylase (Aspa), myelin and lymphocyte protein T cell differentiation protein (Mal1), proteolipid protein 1 (Plp1), myelin-associated oligodendrocyte basic protein (Mobp), Mag, and Mbp along with the key transcription factors Sox10, Myrf, and Nkx6-2 (Emery, 2010a, 2010b). In addition, transcripts for key factors regulating transcription such as Gpr37, mothers against decapentaplegic homolog 7 (Smad7), receptor tyrosine-protein kinase erbB-3, survival of motor neuron protein-interacting protein 1 (Sip1/Zeb2; Brinkmann et al., 2008; Weng et al., 2012) along with transcripts for enzymes that play a key role in lipid biogenesis, such as elongation of very long chain fatty acids protein 7 (Elovl7) and ceramide synthase 2 (Lass2), are decreased with loss of ZFP191. In contrast, very few (14) genes have increased mRNA levels with loss of ZFP191 in both the whole brain and mature oligodendrocytes; these include inhibitor of differentiation 3 (Id3), lunatic fringe (Lfng), and apolipoprotein E (Apoe).

Figure 2.

Figure 2.

A Venn diagram comparing the number of transcripts with decreased expression in Zfp191−/− whole brain compared with Zfp191+/+ whole brain (red) and transcripts with decreased expression in Zfp191−/− oligodendrocytes compared with Zfp191+/+ oligodendrocytes (blue).

There are 177 transcripts that have increased levels in both OPCs and oligodendrocytes that do not express ZFP191 (Figure 3). Several of these transcripts encode proteins that play a role in the control of oligodendrocyte development by repressing maturation such as Id2, Wnt5a/7a, Hdac1, Sox5, and paired-box 7 (Pax7; Liu et al., 2006; Emery, 2010a, 2010b; Fulton et al., 2011; Kuspert and Wegner, 2015). We noted that 1,522 transcripts that are normally decreased upon differentiation from the OPC to oligodendrocyte stage (Zhang et al., 2014) are not suppressed in mature oligodendrocytes that lack ZFP191. These transcripts include Dll1, Ascl1/Mash1, c-Myc, Notch1, Pdgfra, and Sox2/4/6/9/21. Many of these factors are known to play a role in transcriptional regulation. Elevation of these transcript levels may inappropriately maintain the expression of downstream genes that promote OPC identity and prevent maturation.

Figure 3.

Figure 3.

A Venn diagram comparing the number of transcripts (A) with decreased expression in Zfp191−/− OPCs compared with Zfp191+/+ OPCs (light red) and Zfp191−/− oligodendrocytes compared with Zfp191+/+ oligodendrocytes (light blue). A Venn diagram comparing transcripts (B) with increased expression in Zfp191/ OPCs compared with Zfp191+/+ OPCs (dark red) and Zfp191/ oligodendrocytes compared with Zfp191+/+ oligodendrocytes (dark blue). Note. OPCs = oligodendrocyte progenitor cell.

Transcription Factor Expression Is Perturbed With Loss of Zfp191

Loss of Zfp191 expression in the brain perturbs the expression of 25 genes that encode transcription factors as identified by the Animal Transcription Factor Database (AnimalTFDB) and Riken Transcription Factor Database (TFdb; (Kanamori et al., 2004; Zhang et al., 2012). A majority of these transcripts (21) have reduced expression levels in Zfp191null brain.

In isolated and cultured OPCs, loss of Zfp191 expression perturbs the expression of 58 transcription factor transcripts. In contrast to the whole brain data, the majority of these transcripts have increased expression (41) with loss of ZFP191. Pax7 has an approximately 24,000 fold increase in ZFP191null OPCs (this high fold change is due to the absence of detectable Pax7 mRNA in Zfp191+/+ cells). In cultured oligodendrocytes, we identified 558 transcripts that encode putative transcription factors that have perturbed expression with the loss of ZFP191. Table 7 lists the 10 transcripts that have the greatest fold change in Zfp191null oligodendrocytes. Our data demonstrate that loss of ZFP191 reduces expression of Myrf, Nkx6-2, and Olig1, all of which play a vital role in oligodendrocyte differentiation and myelination (Emery, 2010a, 2010b). As with the OPCs, loss of ZFP191 in oligodendrocytes results in more increases in transcription factor transcripts (333) than decreases. Similar to what was seen with OPCs, Pax7 has the largest fold change (241-fold) in Zfp191null oligodendrocytes.

Table 7.

Top 10 Transcription Factor Transcripts With Reduced Expression in Zfp191null Cultured Oligodendrocytes.

Gene Fold change Zfp191+/+ RPKM
Transcription factors with reduced expression in Zfp191null cultured oligodendrocytes
Scx 26.29 8.14
Onecut2 20.52 4.06
Zfp457* 18.23 1.11
Irx5 15.74 1.98
Pou3f1 15.52 19.3
Utf1 14.07 1.17
Mafa 11.69 1.07
Tle6* 10.19 3.43
Hes3* 8.96 11.3
Rbpjl* 8.40 2.23

RNA sequencing was performed on RNA samples isolated from Zfp191null and Zfp191+/+ oligodendrocytes cultured in vitro (n = 2 for each genotype). Transcription factor transcripts were compiled from AnimalTFDB and TFdb (Kanamori et al., 2004; Zhang et al., 2012). Transcription factor transcripts listed for Zfp191+/+ whole brains had a RPKM value ≥0.5, a ≥ 1.5-fold change when comparing Zfp191+/+ versus Zfp191null oligodendrocytes, p < .001, and sorted by RPKM value. *=Gene expression is also reduced in Zfp191null OPCs.

The Perturbation of the Transcriptome Is Primarily Due to Loss of ZFP191 Rather Than the Absence of Myelin

The lack of ZFP191 results in profound CNS hypomyelination, which might have a secondary effect on the transcriptome. To distinguish transcripts that are affected primarily through the loss of ZFP191 from those that are perturbed due to the loss of myelin, we examined the transcriptome of the well-characterized hypomyelinated shiverer mouse, in which the hypomyelination is the result of a spontaneous null mutation in the Mbp gene (Readhead et al., 1987). We performed RNA sequencing on P21 shiverer whole-brain RNA samples, as well as RNA isolated from primary OPCs and oligodendrocytes similar to the Zfp191−/− datasets. The loss of Mbp in P21 whole brain results in the perturbation of 93 transcripts (Tables S8 and S9). The majority of these transcripts were expressed at a higher level in shiverer mutant mice (67 transcripts; Tables 8A and B, 9A and B). Transcripts that were more abundant in the shiverer brain include Nkx6-2, Erbb3 and Apoe. Transcripts that had a lower expression level in the shiverer mouse brains compared with Mbp+/+ littermates include Mbp, UDP galactosyltransferase 8A (Ugt8a), Fa2h, Mal, gelsolin (Gsn), lanosterol synthase (Lss), squalene epoxidase (Sqle), Hmgcr, and Plp1. Examining the altered transcripts for KEGG pathway analysis revealed that the loss of MBP in the whole brain perturbs phosphatidylinositol signaling along with sterol biosynthesis.

Table 8.

Top 10 Transcripts That Have Decreased Expression in Shiverer Whole Brains.

Gene Fold change Mbp+/+ RPKM
A. Genes sorted by Mbp+/+ transcript RPKM
Plp1 1.61 1120.00
Mbp 33.68 506.00
Mal 2.23 178.00
Ugt8a 3.19 122.00
Trf 2.31 69.30
Scd1 1.83 44.00
Apod 2.17 40.30
Gsn 1.81 33.60
Hmgcr 1.61 29.90
Fa2h 2.74 26.40
B. Genes sorted by fold change for Mbp+/+ transcripts ≥ 7 RPKM
Mbp 33.68 506.00
Ugt8a 3.19 122.00
Fa2h 2.74 26.40
Trf 2.31 69.30
Mal 2.23 178.00
Apod 2.17 40.30
Anln 2.113 8.02
Sc4mol 2.012 14.1

RNA sequencing was performed on Mbpshi and Mbp+/+ whole-brain RNA samples (n = 2 for each genotype). Transcripts listed for Mbp+/+ whole brains in A had a p < .001 fold change when comparing Mbp+/+ versus Mbpshi whole brains and are sorted by RPKM value. Transcripts listed for Mbp+/+ whole brains in B had an RPKM value ≥7, a p < .001 fold change when comparing Mbp+/+ versus Mbpshi whole brains, and are sorted by fold changes.

Table 9.

Top 10 Transcripts That Have Increased Expression in Shiverer Whole Brains.

Gene Fold change Mbpshi RPKM
A. Genes sorted by Mbpshi transcript RPKM
Apoe 1.60 752.00
Ptms 1.62 228.00
Ptgds 1.98 138.00
Csrp1 1.72 87.80
Sirt2 1.84 70.90
S100a1 1.76 55.80
Nfasc 1.71 53.90
Map4k4 1.53 45.60
P4hb 1.52 41.00
Nudc 1.53 38.20
B. Genes sorted by fold change for Mbpshi transcripts ≥ 7 RPKM
Gsbs 3.39 28.10
Car14 2.77 14.80
Pls1 2.70 7.77
Tmem2 2.15 8.09
Phlda1 2.05 14.10
H2afj 2.04 17.60
Adamts4 2.04 15.00
Rras2 2.02 17.60
Ptgds 1.98 138.00
Hsd17b7 1.98 10.10

RNA sequencing was performed on Mbpshi and Mbp+/+ whole-brain RNA samples (n = 2 for each genotype). Transcripts listed for Mbpshi whole brains in A had a p < 0.001 fold change when comparing Mbpshi versus Mbp+/+ whole brains and are sorted by RPKM value. Transcripts listed for Mbpshi whole brains in B had an RPKM value ≥7, a p < .001 fold change when comparing Mbpshi versus Mbp+/+ whole brains, and are sorted by fold changes.

Mbp expression loss in OPCs resulted in the perturbation of 10 transcripts, all of which had low RPKM values and small changes (Tables S10 and S11). This is expected as Mbp is upregulated upon exit of the OPC stage. The loss of MBP in mature oligodendrocytes perturbs 387 transcripts; 311 of those transcripts are expressed at a lower abundance with the absence of MBP (Tables S12 and S13; Table 10A and B along with Table 11A and B).

Table 10.

Top 10 Transcripts That Have Reduced Expression in Shiverer Oligodendrocytes.

Gene Fold change Mbp+/+ RPKM
A. Genes sorted by Mbp+/+ transcript RPKM
Mbp 99.90 3150.00
Ugt8a 1.52 721.00
Ddr1 1.52 517.00
Mog 1.78 498.00
Phyhipl 1.54 417.00
Glul 1.56 415.00
Ptgds 2.92 377.00
Nrbp2 1.56 268.00
Cryab 2.72 252.00
Qdpr 1.70 239.00
B. Genes sorted by fold change for Mbp+/+ transcripts ≥ 7 RPKM
Mbp 99.90 3150.00
Stac2 5.75 7.18
Aqp1 3.95 9.78
Hrk 3.94 8.30
Eef1a2 3.54 7.88
Ly6a 3.36 17.10
Atp1a3 3.14 10.90
Ptgds 2.92 377.00
A830039N20Rik 2.85 12.70
Kcnma1 2.85 7.28

RNA sequencing was performed on RNA isolated from Mbpshi and Mbp+/+ oligodendrocytes cultured in vitro (n = 2 for each genotype). Transcripts listed for Mbp+/+ oligodendrocytes in A had a p < .001 fold change when comparing Mbp+/+ versus Mbpshi in oligodendrocytes and are sorted by RPKM value. Transcripts listed for Mbp+/+ oligodendrocytes in B had a RPKM value ≥7, a p < .001 fold change when comparing Mbp+/+ versus Mbpshi in oligodendrocytes, and are sorted by fold changes.

Table 11.

Top 10 Transcripts That Have Increased Expression in Shiverer Oligodendrocytes.

Gene Fold change Mbpshi RPKM
A. Genes sorted by Mbpshi transcript RPKM
Cyb5 1.72 153.00
Rap2a 1.76 85.80
Chst2 1.53 84.40
Sema6a 1.59 82.20
Sema6d 1.68 60.40
Mmd2 1.67 54.80
Dusp15 1.58 49.50
Cntn1 1.56 45.70
Mapre2 1.71 39.30
Fam107b 2.17 34.50
B. Genes sorted by fold change for Mbpshi transcripts > 7 RPKM
Dct 6.32 16.50
Alox5 2.80 14.60
Fam107b 2.17 34.50
Daam2 1.93 9.02
Tmprss5 1.83 11.20
Capn5 1.80 24.70
Rap2a 1.76 85.80
Ndrg2 1.75 17.80
Kcna2 1.74 20.00
Id4 1.72 8.26

RNA sequencing was performed on RNA samples isolated from Mbpshi and Mbp+/+ oligodendrocytes cultured in vitro (n = 2 for each genotype). Transcripts listed for Mbpshi oligodendrocytes in A had a p < .001 fold change when comparing Mbpshi versus Mbp+/+ in oligodendrocytes and are sorted by RPKM value. Transcripts listed for Mbpshi oligodendrocytes in B had an RPKM value ≥7, a p < .001 fold change when comparing Mbpshi versus Mbp+/+ in oligodendrocytes, and are sorted by fold changes.

It is striking that approximately 75% of the transcripts that are reduced with loss of Mbp expression are also reduced with the loss of Zfp191 expression (Figure 4). Transcripts that have reduced expression include Mbp, Mog, Ugt8a, and Fasn, all key transcripts involved in oligodendrocyte development and maturation. When assessing the transcriptional differences detected in total brain RNA, the comparison is even more striking as 25 of the 26 transcripts that have decreased expression with loss of Mbp expression are also decreased with loss of Zfp191−/− expression (Figure 5(a)). Nevertheless, there are only four transcripts that have increased expression in both mouse models of hypomyelination in the whole brain (Figure 5(b)). It is clear from these analyses that the vast majority of genes that demonstrate altered expression in the Zfp191 mutants are expressed normally in Mbpshi mice.

Figure 4.

Figure 4.

A Venn diagram comparing transcripts with decreased expression in Mbpshi oligodendrocytes compared with Mbp+/+ oligodendrocytes (red) and transcripts with decreased expression in Zfp191/ oligodendrocytes compared with Zfp191+/+ oligodendrocytes (blue).

Figure 5.

Figure 5.

A Venn diagram comparing transcripts (A) with decreased expression in Mbpshi whole brain compared with Mbp+/+ whole brain (red) and Zfp191/ whole brain compared with Zfp191+/+ whole brain (blue). A Venn diagram comparing transcripts (B) with increased expression in Mbpshi whole brain compared with Mbp+/+ whole brain (red) and Zfp191/ whole brain compared with Zfp191+/+ whole brain (blue).

Disrupted Cholesterol Biosynthesis Is a Transcriptional Fingerprint of Hypomyelination

The cholesterol biosynthetic pathway is disrupted in both the Zfp191 and Mbp mutants examined here. Table 12 shows that both mouse models have reduced expression of a number of transcripts required for proper cholesterol biosynthesis, including the rate-limiting enzyme HMGCR. The disruption of the cholesterol biosynthesis pathway in these two models suggests that this is a transcriptional signature of hypomyelination (Figure 6). Interestingly, the expression level of these transcripts was not perturbed in isolated Zfp191null or shiverer OPCs or oligodendrocytes. Unlike the oligodendrocytes in the brain, primary cultured oligodendrocytes do not make compact myelin. Therefore, we propose that the observed perturbation in the cholesterol biosynthetic pathway observed only in the brain and not in the primary cultured cells is secondary to the lack of myelin production.

Table 12.

Genes Perturbed in Fatty Acid Degradation for Cholesterol Production.

Zfp191−/− brain
Shiverer brain
Gene Fold change RPKM for Zfp191+/+ Fold change RPKM for Mbp+/+
Lss 2.13 7.50 1.72 6.62
Dhcr7 1.71 9.78 1.60 8.53
Sc5d 1.82 29.50 1.59 19.30
Sqle 1.82 26.50 1.68 24.90
Cyp51 1.99 23.20 1.93 20.90
Sc4mol 2.21 16.80 2.01 14.10
Hmgcr 1.66 28.20 1.60 29.90
Fdft1 1.80 19.00 1.61 14.30
Mvd 1.76 9.34 N.S. 7.47
Nsdhl 1.70 7.97 N.S. 9.17

RNA sequencing was performed on Zfp191+/+ and Zfp191null whole-brain RNA samples along with Mbp+/+ and Mbpshi whole-brain RNA samples (n = 2 for each genotype). Transcripts listed had a RPKM value ≥0.5, a ≥ 1.5-fold change when comparing Zfp191+/+ versus Zfp191null and Mbp+/+ versus Mbpshi in whole brains, and p < .001. N.S. = not significant.

Figure 6.

Figure 6.

Cholesterol biosynthesis pathway transcripts are disrupted in hypomyelinated brains. Yellow boxes denote chemical compounds involved in this pathway. White, blue, or red boxes denote the transcripts involved in this pathway. Red boxes denote transcripts that have reduced expression in the Zfp191null whole brain. Blue boxes denote transcripts that have reduced expression in both the Zfp191null and shiverer whole brains. White boxes denote transcripts that are not affected.

To confirm that the expression levels of key cholesterol biosynthetic transcripts are perturbed, reverse-transcriptase PCR (RT-PCR) was performed (Figure S1).

Discussion

ZFP191 Plays a Key Role in Oligodendrocyte Development and Myelination

In the current study, we examined the role that the putative transcription factor ZFP191 has on the integrity of the transcriptome using high-throughput sequencing of RNA isolated from total brain, as well as isolated oligodendrocyte lineage cells. We first examined how loss of ZFP191 affects the transcriptome of the P21 whole mouse brain. We find that most transcripts that had decreased expression with loss of Zfp191 are associated with oligodendrocyte lineage cells, which is consistent with the hypomyelinating phenotype that these mutant animals display (Howng et al., 2010). Transcripts that have increased expression as a result of loss of Zfp191 expression are associated with gliosis. This gliotic response may be the result of loss of Zfp191 expression in astrocytes and microglia, but it could also reflect a secondary response to the impairment of oligodendrocyte function and myelin production. Loss of Zfp191 expression perturbs the transcriptome of in vitro cultured OPCs. This implies that ZFP191 has a function prior to the generation of oligodendrocytes. The loss of Zfp191 expression in isolated oligodendrocytes results in a perturbation of ∼5,500 transcripts. Transcripts, such as Mbp, Mog, Mobp, and Cnp, for proteins involved in the generation and function of myelin were decreased with loss of Zfp191 expression. The majority of transcripts (∼75%) that had lower expression in the Zfp191/− whole brain also had lower expression in Zfp191−/− oligodendrocytes (Figure 2), demonstrating that the perturbation of the whole brain transcriptome is due mainly to the perturbation of oligodendrocytes.

Recently, it has been reported that patients hemizygous for 18q chromosomal deletions that include the region that contains the Zfp191 human ortholog ZNF24 display seizures and tremors, suggestive of myelin abnormalities (Cody et al., 2015). Interestingly, OPCs and oligodendrocytes that are heterozygous for the Zfp191 null mutation display transcriptome alterations similar to the homozygous mutant cells, albeit to a lesser extent (data not shown). This raises the possibility that a subset of human disorders with 18q deletions might be due, at least in part, to ZNF24 haploinsufficiency.

Zfp191 Plays a Role in the Transcriptional Networks That Govern Oligodendrocyte Differentiation

Due to the large number of transcripts perturbed from lack of Zfp191 expression, we examined whether transcription factor networks were disrupted. Indeed, with loss of Zfp191 expression, several critical transcription factor transcripts such as Nkx6.2, Sox10, and Myrf had decreased expression in cultured oligodendrocytes (Hornig et al., 2013). These transcription factors are mandatory for oligodendrocyte differentiation, as shown in genetic ablation studies (Stolt et al., 2002; Koenning et al., 2012; Mei et al., 2013). These data raise the possibility that ZFP191 functions, at least in part, upstream of many critical oligodendrocyte transcription factors including Sox10 and Myrf.

In the absence of Zfp191 expression, the transcripts for transcriptional repressors Id2/4 and Hes1/5 are increased in Zfp191null oligodendrocytes. Normally, the expression of these genes decreases with differentiation from the OPC to mature oligodendrocyte stage (Dugas et al., 2006; Zhang et al., 2014), and this downregulation has been shown to be required for the proper differentiation of OPCs into mature oligodendrocytes (Norton, 2000; Wang et al., 2001; Wu et al., 2003; Liu et al., 2006; Ogata et al., 2011). The continued expression of these transcripts suggests that Zfp191null oligodendrocytes have not fully differentiated into cells capable of myelinating axons. ZFP191 may play a direct role in downregulating these transcripts or this may represent a secondary effect associated with the absence of ZFP191.

ZFP191 Plays a Role in Signaling Cascades That Control Oligodendrocyte Differentiation

The Notch signaling pathway has been shown to be important for oligodendrocyte differentiation (Hu et al., 2003; Popko, 2003). We find that the transcripts of the Notch signaling effectors Dll3 and Lfng along with the downstream target recombination signal binding protein for immunoglobulin kappa J region-like (Rbpjl) are reduced in OPCs derived from the Zfp191null mice. These data suggest that ZFP191 may play a role in the regulation of the Notch pathway in oligodendrocytes and through its absence may prevent proper maturation and myelin production. Our data show that several additional pathways are perturbed with loss of Zfp191 expression such as the Erbb, MAPK, and Wnt signaling cascades.

The inhibitory effect of the Wnt signaling pathway is critical for oligodendrocyte differentiation (Fancy et al., 2009; Rosenberg and Chan, 2009). We find that the Wnt signaling effectors low-density lipoprotein receptor-related protein 5, frizzled homolog 1, and smoothened homolog 1 (Lrp5, Fzd1, and Smo1) are increased in the oligodendrocytes derived from the Zfp191null mice. These data suggest that ZFP191 may play a role in proper regulation of the Wnt pathway in oligodendrocytes.

In addition, loss of Zfp191 affects the expression of Wnt7a, which is detected at approximately 20-fold higher level in the mutant oligodendrocytes. WNT7A has been shown to affect the developing brain as both an autocrine and a paracrine signaling molecule (Qu et al., 2013). Functioning as an autocrine signaling molecule, WNT7a maintains OPCs in their progenitor state and prevents differentiation. When functioning as a paracrine signaling molecule, WNT7a promotes endothelial cells to initiate angiogenesis in white matter areas (Yuen et al., 2014). The perturbed expression of Wnt7a in the Zfp191null-derived oligodendrocyte lineage cells may suggest that ablation of Zfp191 may affect other cell types in the brain in a paracrine fashion mediated by WNT7A. This may explain some of the differences detected between the whole brain transcriptome compared with isolated oligodendrocyte lineage cells and may explain, at least in part, the effect of ablation of Zfp191 on non-oligodendrocyte lineage cell-specific transcripts in the brain.

The Disruption of the Oligodendrocyte Transcriptome Primarily Results From the Loss of ZFP191 Not the Absence of Myelin Production

To examine whether the altered gene expression in the Zfp191 mutant CNS is due to the direct loss of ZFP191 or whether it represents a secondary consequence of the inability to produce myelin, we performed RNA sequencing using the shiverer mouse. The loss of MBP results in 75% fewer transcripts being perturbed in the whole brain than in the Zfp191null mouse. We also observed that fewer transcripts associated with transcriptional control were perturbed with loss of Mbp expression. This seems reasonable as MBP is a structural protein, but it is important to note that expression of Id2/4, Runx1, Atf3, and Scx are altered in both Zfp191null and shiverer oligodendrocytes suggesting that there may be transcription factors that are affected due to the general loss of proper myelin production. Interestingly, previous studies have shown that a small portion of MBP is localized to the nucleus of oligodendrocytes, which may indicate a possible role for this protein in transcriptional control (Pedraza et al., 1997; Smith et al., 2012; Smith et al., 2013). Nevertheless, a direct regulatory effect of MBP on oligodendrocyte gene expression has not been demonstrated. A majority of the transcripts that are perturbed with loss of Mbp expression are also perturbed with loss of Zfp191 expression in oligodendrocytes (Figure 4). This may demonstrate that ZFP191 plays a key role upstream of MBP, particularly as many more transcripts are perturbed with loss of ZFP191 than with MBP.

Hypomyelination Causes a Reduction in Key Transcripts Involved in the Lipid Biosynthesis Pathway

The absence of myelin in the Zfp191null and shiverer mouse whole brains results in the reduction of a number of transcripts that encode key proteins in the cholesterol and lipid biosynthetic pathways. The loss of either ZFP191 or MBP results in similar reductions of Hmgcr, which encodes for the rate-limiting enzyme in cholesterol biosynthesis, and several transcripts that encode for proteins involved in the final steps of this pathway (Figure 6). These data suggest that oligodendrocytes have a feedback system that allows them to regulate myelin lipid synthesis depending on their myelinating state. The control of cholesterol homeostasis is critical for myelination (Saher et al., 2005; Verheijen et al., 2009), and defects in lipid synthesis have been linked to demyelination (Rolyan et al., 2015). The transcription factors sterol regulatory element-binding proteins (SREBPs; encoded by the SREBF1 and SREBF2 genes) regulates nine of the genes that encode enzymes required for cholesterol biosynthesis (Sakakura et al., 2001). In Zfp191null OPCs and oligodendrocytes, SREBF1 and SREBF2 are expressed more abundantly than in Zfp191+/+ cells. Although both of the SREBPs transcripts are more abundant, the mRNA levels of their downstream targets such as Hmgcr, Sqle, and Lss are not altered in Zfp191null OPCs and oligodendrocytes, suggesting a more complex level of regulation. Moreover, SREBF1 and SREBF2 expression is not perturbed in the hypomyelinated shiverer mouse, further suggesting that these transcription factors are not the myelin sensors that regulate lipid biosynthesis. Data from these models of hypomyelination may help identify novel potential sensors in oligodendrocytes for proper cholesterol and lipid biosynthesis. Lipid biosynthesis transcripts are also expressed abundantly in many cells in the CNS, particularly astrocytes, which play a key role in providing lipids and cholesterol for neurons (for review, see Pfrieger and Ungerer, 2011). The decrease of key lipid biosynthesis transcripts in these models of hypomyelination may be due to a direct effect on oligodendrocytes or it may reflect a secondary effect of oligodendrocyte perturbation on the homeostatic production of cholesterol by the CNS.

Conclusion

ZFP191 is a putative transcription factor that plays a critical role in CNS myelination (Emery, 2010a, 2010b; Howng et al., 2010; Yu et al., 2013; Kuspert and Wegner, 2015). Therefore, a complete understanding of ZFP191 function is critical. Our data suggest that ZFP191 plays a key role in the transcriptional network that controls oligodendrocyte development and myelination. Loss of ZFP191 primarily perturbs the mature oligodendrocyte transcriptome, although OPC transcriptome alterations demonstrate that loss of ZFP191 is acting early in the oligodendrocyte lineage. We also show that ZFP191 acts, at least in part, upstream of Sox10 and Myrf and may have a critical role in their transcriptional regulation. Many pathways such as MAPK, Notch, Wnt, and Erbb signaling cascades, which are known to play key roles in oligodendrocyte development, are perturbed with the loss of ZFP191. These data suggest that the loss of ZFP191 results in the subsequent decrease in abundance of key transcription factors along with transcripts that play a key role in signal transduction and cholesterol biosynthesis. Therefore, ZFP191 is a central transcriptional regulator of oligodendrocyte development and myelination.

Supplementary Material

Supplementary material
Supplement_Table1.xlsx (34.6KB, xlsx)

Supplementary Material

Supplementary material
Supplement_Table2.xlsx (110.2KB, xlsx)

Supplementary Material

Supplementary material
Supplement_Table3.xlsx (51.4KB, xlsx)

Supplementary Material

Supplementary material
Supplement_Table4.xlsx (88.9KB, xlsx)

Supplementary Material

Supplementary material
Supplement_Table5.xlsx (97.8KB, xlsx)

Supplementary Material

Supplementary material
Supplement_Table6.xlsx (579.4KB, xlsx)

Supplementary Material

Supplementary material
Supplement_Table7.xlsx (584.3KB, xlsx)

Supplementary Material

Supplementary material
Supplement_Table8.xlsx (51.9KB, xlsx)

Supplementary Material

Supplementary material
Supplement_Table9.xlsx (65.2KB, xlsx)

Supplementary Material

Supplementary material
Supplement_Table10.xlsx (35.6KB, xlsx)

Supplementary Material

Supplementary material

Supplementary Material

Supplementary material
Supplement_Table12.xlsx (116.1KB, xlsx)

Supplementary Material

Supplementary material
Supplement_Table13.xlsx (63.7KB, xlsx)

Acknowledgments

We would like to thank Robin Avila and Benjamin L. L. Clayton for their thoughtful discussions. We also thank the University of Chicago Functional Genomics Facility for assistance in high-throughput sequencing.

Summary Statement

The transcriptional program of oligodendrocyte maturation and myelination has not been fully characterized. In this study, we use RNA sequencing to analyze how the loss of the transcription factor zinc finger protein 191 results in the perturbation of oligodendrocyte development.

Author Contribution

J. D. A designed research, performed research, analyzed data, and wrote the paper; B. E. designed research, performed research, analyzed data, and wrote the paper; Y. W. performed research and analyzed data; T. J. L. analyzed data; L. Z. analyzed data; B. T. L. analyzed data; B. P designed research, analyzed data, and wrote the paper.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported from a grant from the National Institutes of Health (R01NS067550) and the National Multiple Sclerosis Society (RG-1501-02797).

Supplemental Material

The online figures and tables are available at http://asn.sagepub.com/supplemental.

References

  1. Anders S., Huber W. (2010) Differential expression analysis for sequence count data. Genome Biology 11: R106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bartlett P. F., Noble M. D., Pruss R. M., Raff M. C., Rattray S., Williams C. A. (1981) Rat neural antigen-2 (RAN-2): A cell surface antigen on astrocytes, ependymal cells, Muller cells and lepto-meninges defined by a monoclonal antibody. Brain Research 204: 339–351. [DOI] [PubMed] [Google Scholar]
  3. Bignami A., Eng L. F., Dahl D., Uyeda C. T. (1972) Localization of the glial fibrillary acidic protein in astrocytes by immunofluorescence. Brain Research 43: 429–435. [DOI] [PubMed] [Google Scholar]
  4. Blankenberg, D., Von Kuster, G., Coraor, N., Ananda, G., Lazarus, R., Mangan, M., … Taylor, J. (2010). Galaxy: A web-based genome analysis tool for experimentalists. Current Protocols in Molecular Biology/edited by Frederick M Ausubel [et al] Chapter 19:Unit 19.10.1-21. [DOI] [PMC free article] [PubMed]
  5. Brinkmann B. G., Agarwal A., Sereda M. W., Garratt A. N., Muller T., Wende H., Nave K. A. (2008) Neuregulin-1/ErbB signaling serves distinct functions in myelination of the peripheral and central nervous system. Neuron 59: 581–595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bujalka H., Koenning M., Jackson S., Perreau V. M., Pope B., Hay C. M., Emery B. (2013) MYRF is a membrane-associated transcription factor that autoproteolytically cleaves to directly activate myelin genes. PLoS Biology 11: e1001625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chen Y., Wu H., Wang S., Koito H., Li J., Ye F., Lu Q. R. (2009) The oligodendrocyte-specific G protein-coupled receptor GPR17 is a cell-intrinsic timer of myelination. Nature Neuroscience 12: 1398–1406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cheng X., Wang Y., He Q., Qiu M., Whittemore S. R., Cao Q. (2007) Bone morphogenetic protein signaling and olig1/2 interact to regulate the differentiation and maturation of adult oligodendrocyte precursor cells. Stem Cells 25: 3204–3214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cody J. D., Sebold C., Heard P., Carter E., Soileau B., Hasi-Zogaj M., Hale D. E. (2015) Consequences of chromsome18q deletions. American Journal of Medical Genetics Part C, Seminars in Medical Genetics 169: 265–280. [DOI] [PubMed] [Google Scholar]
  10. Dugas J. C., Tai Y. C., Speed T. P., Ngai J., Barres B. A. (2006) Functional genomic analysis of oligodendrocyte differentiation. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 26: 10967–10983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Edelstein L. C., Collins T. (2005) The SCAN domain family of zinc finger transcription factors. Gene 359: 1–17. . [DOI] [PubMed] [Google Scholar]
  12. Emery B. (2010a) Regulation of oligodendrocyte differentiation and myelination. Science 330: 779–782. [DOI] [PubMed] [Google Scholar]
  13. Emery B. (2010b) Transcriptional and post-transcriptional control of CNS myelination. Current Opinion in Neurobiology 20: 601–607. [DOI] [PubMed] [Google Scholar]
  14. Emery B., Agalliu D., Cahoy J. D., Watkins T. A., Dugas J. C., Mulinyawe S. B., Barres B. A. (2009) Myelin gene regulatory factor is a critical transcriptional regulator required for CNS myelination. Cell 138: 172–185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Emery B., Dugas J. C. (2013) Purification of oligodendrocyte lineage cells from mouse cortices by immunopanning. Cold Spring Harbor Protocols 2013: 854–868. [DOI] [PubMed] [Google Scholar]
  16. Fancy S. P., Baranzini S. E., Zhao C., Yuk D. I., Irvine K. A., Kaing S., Rowitch D. H. (2009) Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes & Development 23: 1571–1585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Feigenson K., Reid M., See J., Crenshaw I. E., Grinspan J. B. (2011) Canonical Wnt signalling requires the BMP pathway to inhibit oligodendrocyte maturation. ASN Neuro 3: e00061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Friedman B. A., Maniatis T. (2011) ExpressionPlot: A web-based framework for analysis of RNA-Seq and microarray gene expression data. Genome Biology 12: R69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Fulton D. L., Denarier E., Friedman H. C., Wasserman W. W., Peterson A. C. (2011) Towards resolving the transcription factor network controlling myelin gene expression. Nucleic Acids Research 39: 7974–7991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Giardine B., Riemer C., Hardison R. C., Burhans R., Elnitski L., Shah P., Nekrutenko A. (2005) Galaxy: A platform for interactive large-scale genome analysis. Genome Research 15: 1451–1455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Goecks J., Nekrutenko A., Taylor J., Galaxy T. (2010) Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biology 11: R86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Grandbarbe L., Bouissac J., Rand M., Hrabe de Angelis M., Artavanis-Tsakonas S., Mohier E. (2003) Delta-Notch signaling controls the generation of neurons/glia from neural stem cells in a stepwise process. Development 130: 1391–1402. [DOI] [PubMed] [Google Scholar]
  23. Grinspan J. B., Edell E., Carpio D. F., Beesley J. S., Lavy L., Pleasure D., Golden J. A. (2000) Stage-specific effects of bone morphogenetic proteins on the oligodendrocyte lineage. Journal of Neurobiology 43(1): 1–17. [PubMed] [Google Scholar]
  24. Hammond E., Lang J., Maeda Y., Pleasure D., Angus-Hill M., Xu J., Guo F. (2015) The Wnt effector transcription factor 7-like 2 positively regulates oligodendrocyte differentiation in a manner independent of Wnt/beta-catenin signaling. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 35: 5007–5022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Hornig J., Frob F., Vogl M. R., Hermans-Borgmeyer I., Tamm E. R., Wegner M. (2013) The transcription factors Sox10 and Myrf define an essential regulatory network module in differentiating oligodendrocytes. PLoS Genetics 9: e1003907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Howng S. Y., Avila R. L., Emery B., Traka M., Lin W., Watkins T., Popko B. (2010) ZFP191 is required by oligodendrocytes for CNS myelination. Genes & Development 24: 301–311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Hu Q. D., Ang B. T., Karsak M., Hu W. P., Cui X. Y., Duka T., Xiao Z. C. (2003) F3/contactin acts as a functional ligand for Notch during oligodendrocyte maturation. Cell 115: 163–175. [DOI] [PubMed] [Google Scholar]
  28. Huang da W., Sherman B. T., Lempicki R. A. (2009a) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols 4: 44–57. [DOI] [PubMed] [Google Scholar]
  29. Huang da W., Sherman B. T., Lempicki R. A. (2009b) Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Research 37(1): 1–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Kanamori M., Konno H., Osato N., Kawai J., Hayashizaki Y., Suzuki H. (2004) A genome-wide and nonredundant mouse transcription factor database. Biochemical and Biophysical Research Communications 322: 787–793. [DOI] [PubMed] [Google Scholar]
  31. Kanehisa M., Goto S. (2000) KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Research 28: 27–30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Kanehisa M., Goto S., Sato Y., Kawashima M., Furumichi M., Tanabe M. (2014) Data, information, knowledge and principle: Back to metabolism in KEGG. Nucleic Acids Research 42: D199–D205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Koenning M., Jackson S., Hay C. M., Faux C., Kilpatrick T. J., Willingham M., Emery B. (2012) Myelin gene regulatory factor is required for maintenance of myelin and mature oligodendrocyte identity in the adult CNS. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 32: 12528–12542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Kuspert M., Wegner M. (2015) SomethiNG 2 talk about-Transcriptional regulation in embryonic and adult oligodendrocyte precursors. Brain Research 1638: 167–182. [DOI] [PubMed] [Google Scholar]
  35. Langmead B., Trapnell C., Pop M., Salzberg S. L. (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biology 10: R25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Li H., Lu Y., Smith H. K., Richardson W. D. (2007) Olig1 and Sox10 interact synergistically to drive myelin basic protein transcription in oligodendrocytes. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 27: 14375–14382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Liu A., Li J., Marin-Husstege M., Kageyama R., Fan Y., Gelinas C., Casaccia-Bonnefil P. (2006) A molecular insight of Hes5-dependent inhibition of myelin gene expression: Old partners and new players. The EMBO Journal 25: 4833–4842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Matthieu J. M., Amiguet P. (1990) Myelin/oligodendrocyte glycoprotein expression during development in normal and myelin-deficient mice. Developmental Neuroscience 12: 293–302. [DOI] [PubMed] [Google Scholar]
  39. Mei F., Wang H., Liu S., Niu J., Wang L., He Y., Xiao L. (2013) Stage-specific deletion of Olig2 conveys opposing functions on differentiation and maturation of oligodendrocytes. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 33: 8454–8462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Menn B., Garcia-Verdugo J. M., Yaschine C., Gonzalez-Perez O., Rowitch D., Alvarez-Buylla A. (2006) Origin of oligodendrocytes in the subventricular zone of the adult brain. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 26: 7907–7918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Miller R. H., Dinsio K., Wang R., Geertman R., Maier C. E., Hall A. K. (2004) Patterning of spinal cord oligodendrocyte development by dorsally derived BMP4. Journal of Neuroscience Research 76: 9–19. [DOI] [PubMed] [Google Scholar]
  42. Nakatani H., Martin E., Hassani H., Clavairoly A., Maire C. L., Viadieu A., Parras C. (2013) Ascl1/Mash1 promotes brain oligodendrogenesis during myelination and remyelination. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 33: 9752–9768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Norton J. D. (2000) ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. Journal of Cell Science 113(Pt 22): 3897–3905. [DOI] [PubMed] [Google Scholar]
  44. Ogata T., Ueno T., Hoshikawa S., Ito J., Okazaki R., Hayakawa K., Akai M. (2011) Hes1 functions downstream of growth factors to maintain oligodendrocyte lineage cells in the early progenitor stage. Neuroscience 176: 132–141. [DOI] [PubMed] [Google Scholar]
  45. Pedraza L., Fidler L., Staugaitis S. M., Colman D. R. (1997) The active transport of myelin basic protein into the nucleus suggests a regulatory role in myelination. Neuron 18: 579–589. [DOI] [PubMed] [Google Scholar]
  46. Pfaffl M. W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research 29: e45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Pfrieger F. W., Ungerer N. (2011) Cholesterol metabolism in neurons and astrocytes. Progress in Lipid Research 50: 357–371. [DOI] [PubMed] [Google Scholar]
  48. Popko B. (2003) Notch signaling: A rheostat regulating oligodendrocyte differentiation? Developmental Cell 5: 668–669. [DOI] [PubMed] [Google Scholar]
  49. Qu Q., Sun G., Murai K., Ye P., Li W., Asuelime G., Shi Y. (2013) Wnt7a regulates multiple steps of neurogenesis. Molecular and Cellular Biology 33: 2551–2559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Readhead C., Popko B., Takahashi N., Shine H. D., Saavedra R. A., Sidman R. L., Hood L. (1987) Expression of a myelin basic protein gene in transgenic shiverer mice: correction of the dysmyelinating phenotype. Cell 48: 703–712. [DOI] [PubMed] [Google Scholar]
  51. Richardson W. D., Kessaris N., Pringle N. (2006) Oligodendrocyte wars. Nature Reviews. Neuroscience 7: 11–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Roach A., Takahashi N., Pravtcheva D., Ruddle F., Hood L. (1985) Chromosomal mapping of mouse myelin basic protein gene and structure and transcription of the partially deleted gene in shiverer mutant mice. Cell 42: 149–155. [DOI] [PubMed] [Google Scholar]
  53. Rolyan H., Tyurina Y. Y., Hernandez M., Amoscato A. A., Sparvero L. J., Nmezi B. C., Padiath Q. S. (2015) Defects of lipid synthesis are linked to the age-dependent demyelination caused by lamin b1 overexpression. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 35: 12002–12017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Rosenberg S. S., Chan J. R. (2009) Modulating myelination: knowing when to say Wnt. Genes & Development 23: 1487–1493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Saher G., Brugger B., Lappe-Siefke C., Mobius W., Tozawa R., Wehr M. C., Nave K. A. (2005) High cholesterol level is essential for myelin membrane growth. Nature Neuroscience 8: 468–475. [DOI] [PubMed] [Google Scholar]
  56. Saher G., Simons M. (2010) Cholesterol and myelin biogenesis. Sub-cellular Biochemistry 51: 489–508. [DOI] [PubMed] [Google Scholar]
  57. Sakakura Y., Shimano H., Sone H., Takahashi A., Inoue N., Toyoshima H., Yamada N. (2001) Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis. Biochemical and Biophysical Research Communications 286: 176–183. [DOI] [PubMed] [Google Scholar]
  58. Samanta J., Kessler J. A. (2004) Interactions between ID and OLIG proteins mediate the inhibitory effects of BMP4 on oligodendroglial differentiation. Development 131: 4131–4142. [DOI] [PubMed] [Google Scholar]
  59. See J., Zhang X., Eraydin N., Mun S. B., Mamontov P., Golden J. A., Grinspan J. B. (2004) Oligodendrocyte maturation is inhibited by bone morphogenetic protein. Molecular and Cellular Neurosciences 26: 481–492. [DOI] [PubMed] [Google Scholar]
  60. Simons M., Nave K. A. (2015) Oligodendrocytes: Myelination and Axonal Support. Cold Spring Harb Perspectives in Biology 8: a020479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Smith G. S., Samborska B., Hawley S. P., Klaiman J. M., Gillis T. E., Jones N., Harauz G. (2013) Nucleus-localized 21.5-kDa myelin basic protein promotes oligodendrocyte proliferation and enhances neurite outgrowth in coculture, unlike the plasma membrane-associated 18.5-kDa isoform. Journal of Neuroscience Research 91: 349–362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Smith G. S., Seymour L. V., Boggs J. M., Harauz G. (2012) The 21.5-kDa isoform of myelin basic protein has a non-traditional PY-nuclear-localization signal. Biochemical and Biophysical Research Communications 422: 670–675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Sommer I., Schachner M. (1981) Monoclonal antibodies (O1 to O4) to oligodendrocyte cell surfaces: An immunocytological study in the central nervous system. Developmental Biology 83: 311–327. [DOI] [PubMed] [Google Scholar]
  64. Stolt C. C., Rehberg S., Ader M., Lommes P., Riethmacher D., Schachner M., Wegner M. (2002) Terminal differentiation of myelin-forming oligodendrocytes depends on the transcription factor Sox10. Genes & Development 16: 165–170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Tsai H. H., Niu J., Munji R., Davalos D., Chang J., Zhang H., Fancy S. P. (2016) Oligodendrocyte precursors migrate along vasculature in the developing nervous system. Science 351: 379–384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Tsuda M., Takahashi S., Takahashi Y., Asahara H. (2003) Transcriptional co-activators CREB-binding protein and p300 regulate chondrocyte-specific gene expression via association with Sox9. The Journal of Biological Chemistry 278: 27224–27229. [DOI] [PubMed] [Google Scholar]
  67. Verheijen M. H., Camargo N., Verdier V., Nadra K., de Preux Charles A. S., Medard J. J., Smit A. B. (2009) SCAP is required for timely and proper myelin membrane synthesis. Proceedings of the National Academy of Sciences of the United States of America 106: 21383–21388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Wang S., Sdrulla A., Johnson J. E., Yokota Y., Barres B. A. (2001) A role for the helix-loop-helix protein Id2 in the control of oligodendrocyte development. Neuron 29: 603–614. [DOI] [PubMed] [Google Scholar]
  69. Wang S., Sdrulla A. D., diSibio G., Bush G., Nofziger D., Hicks C., Barres B. A. (1998) Notch receptor activation inhibits oligodendrocyte differentiation. Neuron 21: 63–75. [DOI] [PubMed] [Google Scholar]
  70. Wang H., Sun R., Liu G., Yao M., Fei J., Shen H. (2008) Characterization of the target DNA sequence for the DNA-binding domain of zinc finger protein 191. Acta Biochimica et Biophysica Sinica (Shanghai) 40: 704–710. [PubMed] [Google Scholar]
  71. Weng Q., Chen Y., Wang H., Xu X., Yang B., He Q., Lu Q. R. (2012) Dual-mode modulation of Smad signaling by Smad-interacting protein Sip1 is required for myelination in the central nervous system. Neuron 73: 713–728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Williams A. J., Blacklow S. C., Collins T. (1999) The zinc finger-associated SCAN box is a conserved oligomerization domain. Molecular and Cellular Biology 19: 8526–8535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Wu Y., Liu Y., Levine E. M., Rao M. S. (2003) Hes1 but not Hes5 regulates an astrocyte versus oligodendrocyte fate choice in glial restricted precursors. Developmental Dynamics: an Official Publication of the American Association of Anatomists 226: 675–689. [DOI] [PubMed] [Google Scholar]
  74. Ye F., Chen Y., Hoang T., Montgomery R. L., Zhao X. H., Bu H., Lu Q. R. (2009) HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nature Neuroscience 12: 829–838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Yu Y., Chen Y., Kim B., Wang H., Zhao C., He X., Lu Q. R. (2013) Olig2 targets chromatin remodelers to enhancers to initiate oligodendrocyte differentiation. Cell 152: 248–261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Yuen T. J., Silbereis J. C., Griveau A., Chang S. M., Daneman R., Fancy S. P., Rowitch D. H. (2014) Oligodendrocyte-encoded HIF function couples postnatal myelination and white matter angiogenesis. Cell 158: 383–396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Zamanian J. L., Xu L., Foo L. C., Nouri N., Zhou L., Giffard R. G., Barres B. A. (2012) Genomic analysis of reactive astrogliosis. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 32: 6391–6410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Zhang H. M., Chen H., Liu W., Liu H., Gong J., Wang H., Guo A. Y. (2012) AnimalTFDB: A comprehensive animal transcription factor database. Nucleic Acids Research 40: D144–149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Zhang Y., Chen K., Sloan S. A., Bennett M. L., Scholze A. R., O'Keeffe S., Wu J. Q. (2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 34: 11929–11947. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary material
Supplement_Table1.xlsx (34.6KB, xlsx)
Supplementary material
Supplement_Table2.xlsx (110.2KB, xlsx)
Supplementary material
Supplement_Table3.xlsx (51.4KB, xlsx)
Supplementary material
Supplement_Table4.xlsx (88.9KB, xlsx)
Supplementary material
Supplement_Table5.xlsx (97.8KB, xlsx)
Supplementary material
Supplement_Table6.xlsx (579.4KB, xlsx)
Supplementary material
Supplement_Table7.xlsx (584.3KB, xlsx)
Supplementary material
Supplement_Table8.xlsx (51.9KB, xlsx)
Supplementary material
Supplement_Table9.xlsx (65.2KB, xlsx)
Supplementary material
Supplement_Table10.xlsx (35.6KB, xlsx)
Supplementary material
Supplementary material
Supplement_Table12.xlsx (116.1KB, xlsx)
Supplementary material
Supplement_Table13.xlsx (63.7KB, xlsx)

Articles from ASN NEURO are provided here courtesy of Taylor & Francis

RESOURCES